<DOC>
	<DOCNO>NCT01762839</DOCNO>
	<brief_summary>The purpose study generate cardiac safety data use supratherapeutic oritavancin dose 1600 mg .</brief_summary>
	<brief_title>A Study Assess Cardiac Safety Oritavancin Healthy Volunteers</brief_title>
	<detailed_description>This study single-center , double-blind , randomize , placebo-controlled parallel design study open label positive-control moxifloxacin arm evaluate effect supratherapeutic dose oritavancin QT QTc interval .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Oritavancin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Able give write informed consent initiation study related procedure willing comply require study procedure . 2 . Healthy , male female 18 60 year old , BMI 18 kg/m2 30 kg/m2 3 . In good health base upon result medical history , physical examination , clinically significant 12lead ECG result , laboratory test result . 4 . Serum magnesium potassium level within normal range screening . 5 . Agree abstain alcohol , caffeine , xanthinecontaining product , kind energy drink consumption grapefruit juice orange juice 48 hour study drug administration completion followup visit . 1 . History immunerelated hypersensitivity reaction glycopeptides ( vancomycin , televancin , daptomycin , teicoplanin ) excipients . Note : patient histaminelike infusion reaction glycopeptide exclude 2 . A rest pulse rate &lt; 50 beat per minute ( bpm ) &gt; 100 bpm 3 . Systolic blood pressure &lt; 90 mmHg diastolic blood pressure &lt; 50 mmHg 4 . A QTcF &gt; 450 msec ( male ) &gt; 470 msec ( female ) 5 . Respiratory difficulty , history asthma chronic obstructive pulmonary disease 6 . Use prescription drug overthecounter ( OTC ) medication herbal preparation within 14 day 5times elimination halflife ( whichever longer ) prior start study ( except acetaminophen ; birth control pill ; implantable injectable birth control ; estrogen , testosterone , and/or progesterone replacement menopausal woman ) 7 . Unwilling abstain smoking duration study . 8 . Any clinicallysignificant , underlie abnormality rhythm , conduction , morphology rest ECG may interfere interpretation QTc interval change 9 . Positive result urine serum human chorionic gonadotropin ( hCG ) test administer screening ( female child bear potential ) 10 . A past medical history clinically significant ECG abnormality family history ( grandparent , parent , sibling ) either long short QT syndrome 11 . Personal history unexplained syncope . 12 . Women pregnant nursing , childbearing potential unwilling use least 2 acceptable method birth control ( eg , prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , barrier method ( ) male partner sterilization ) . Women â‰¥2 year postmenopausal surgically sterile exempt exclusion 13 . A history hypersensitivity moxifloxacin member quinolone class antimicrobial agent 14 . Positive virology screen human immunodeficiency virus ( HIV ) hepatitis B C virus ( HBV HCV , respectively ) 15 . Participated clinical research study involve evaluation investigational drug device within 30 day enrollment 16 . Any condition , opinion investigator would put subject increase risk participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>